-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IGV-001 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IGV-001 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IGV-001 in Glioblastoma Multiforme (GBM) Drug Details: IGV-001 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-7503 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AZD-7503 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Drug Details: AZD-7503 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OLX-301A in Dry (Atrophic) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OLX-301A in Dry (Atrophic) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OLX-301A in Dry (Atrophic) Macular Degeneration Drug Details: OLX-301A is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OLX-301A in Geographic Atrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OLX-301A in Geographic Atrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OLX-301A in Geographic Atrophy Drug Details: OLX-301A is under development for the...
-
Product Insights
Limb-Girdle Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Limb-Girdle Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Limb-Girdle Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Limb-Girdle Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Acromegaly – Drugs In Development, 2023
Global Markets Direct’s, ‘Acromegaly - Drugs In Development, 2023’, provides an overview of the Acromegaly pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Relapsing Remitting Multiple Sclerosis (RRMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Relapsing Remitting Multiple Sclerosis (RRMS) - Drugs In Development, 2023’, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-08 in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AB-08 in Breast Cancer Drug Details: AB-08 is under development for the treatment of breast,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulefnersen Sodium in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulefnersen Sodium in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulefnersen Sodium in Amyotrophic Lateral Sclerosis Drug Details: ION363 is...